Low high-density lipoprotein cholesterol disorders and cardiovascular risk: contribution of associated low-density lipoprotein subclass abnormalities

被引:12
作者
Rosenson, RS [1 ]
机构
[1] Northwestern Univ, Feinberg Sch Med, Prevent Cardiol Ctr, Chicago, IL 60611 USA
关键词
cardiovascular risk; coronary heart disease risk; high-density lipoprotein; low-density lipoprotein; low-density lipoprotein subclasses;
D O I
10.1097/01.hco.0000168534.15085.5d
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Discuss the contribution of low-density lipoprotein subclass abnormalities to cardiovascular risk among individuals with low high-density lipoprotein cholesterol levels. Recent findings Low high-density lipoprotein cholesterol levels are commonly encountered among patients with early onset cardiovascular disease. Most often, a low high-density lipoprotein cholesterol level is not an isolated abnormality, but it is usually associated with a number of other lipoprotein abnormalities. Data from the Framingham Offspring Study demonstrate that among subjects with high-density lipoprotein cholesterol, 1.0 mmol/L (39 mg/dL), low-density lipoprotein particle numbers were considerably higher than indicated by the level of low-density lipoprotein cholesterol because these subjects had excess numbers of small cholesterol-depleted low-density lipoprotein particles. Elevated numbers of low-density lipoprotein particles identify individuals at highest risk for atherosclerotic vascular disease and cardiovascular events. Summary As high levels of low-density lipoprotein particles are a robust predictor of cardiovascular events, strategies targeted at raising low levels of high-density lipoprotein cholesterol must account for low-density lipoprotein particle interactions.
引用
收藏
页码:313 / 317
页数:5
相关论文
共 43 条
[1]  
ALEXANDER CM, 2002, DIABETES CARE, V25, P1198
[2]   Inflammatory/antiinflammatory properties of high-density lipoprotein distinguish patients from control subjects better than high-density lipoprotein cholesterol levels and are favorably affected by simvastatin treatment [J].
Ansell, BJ ;
Navab, M ;
Hama, S ;
Kamranpour, N ;
Fonarow, G ;
Hough, G ;
Rahmani, S ;
Mottahedeh, R ;
Dave, R ;
Reddy, ST ;
Fogelman, AM .
CIRCULATION, 2003, 108 (22) :2751-2756
[3]   Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S [J].
Ballantyne, CM ;
Olsson, AG ;
Cook, TJ ;
Mercuri, MF ;
Pedersen, TR ;
Kjekshus, J .
CIRCULATION, 2001, 104 (25) :3046-3051
[4]   Low-density lipoprotein particle concentration and size as determined by nuclear magnetic resonance spectroscopy as predictors of cardiovascular disease in women [J].
Blake, GJ ;
Otvos, JD ;
Rifai, N ;
Ridker, PM .
CIRCULATION, 2002, 106 (15) :1930-1937
[5]   Effect of pravastatin on LDL particle concentration as determined by NMR spectroscopy: a substudy of a randomized placebo controlled trial [J].
Blake, GJ ;
Albert, MA ;
Rifai, N ;
Ridker, PM .
EUROPEAN HEART JOURNAL, 2003, 24 (20) :1843-1847
[6]   Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol [J].
Brousseau, ME ;
Schaefer, EJ ;
Wolfe, ML ;
Bloedon, LT ;
Digenio, AG ;
Clark, RW ;
Mancuso, JP ;
Rader, DJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (15) :1505-1515
[7]   Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease [J].
Brown, BG ;
Zhao, XQ ;
Chait, A ;
Fisher, LD ;
Cheung, MC ;
Morse, JS ;
Dowdy, AA ;
Marino, EK ;
Bolson, EL ;
Alaupovic, P ;
Frohlich, J ;
Albers, JJ ;
Serafini, L ;
Huss-Frechette, E ;
Wang, S ;
DeAngelis, D ;
Dodek, A .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 345 (22) :1583-1592
[8]   Raising high-density lipoprotein in humans through inhibition of cholesteryl ester transfer protein: An initial multidose study of torcetrapib [J].
Clark, RW ;
Sutfin, TA ;
Ruggeri, RB ;
Willauer, AT ;
Sugarman, ED ;
Magnus-Aryitey, G ;
Cosgrove, PG ;
Sand, TM ;
Wester, RT ;
Williams, JA ;
Perlman, ME ;
Bamberger, MJ .
ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2004, 24 (03) :490-497
[9]   Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) [J].
Cleeman, JI ;
Grundy, SM ;
Becker, D ;
Clark, LT ;
Cooper, RS ;
Denke, MA ;
Howard, WJ ;
Hunninghake, DB ;
Illingworth, DR ;
Luepker, RV ;
McBride, P ;
McKenney, JM ;
Pasternak, RC ;
Stone, NJ ;
Van Horn, L ;
Brewer, HB ;
Ernst, ND ;
Gordon, D ;
Levy, D ;
Rifkind, B ;
Rossouw, JE ;
Savage, P ;
Haffner, SM ;
Orloff, DG ;
Proschan, MA ;
Schwartz, JS ;
Sempos, CT ;
Shero, ST ;
Murray, EZ .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (19) :2486-2497
[10]   Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS [J].
Downs, JR ;
Clearfield, M ;
Weis, S ;
Whitney, E ;
Shapiro, DR ;
Beere, PA ;
Langendorfer, A ;
Stein, EA ;
Kruyer, W ;
Gotto, AM .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20) :1615-1622